-
$ONDS: Sales Hit $83.8 Million; The Loss Still Got Wider earnings_post · 2026-08-13-ONDS · Aug 14, 4:31 AM ETNet loss was $89.7 million. Adjusted EBITDA was a $50.6 million hole. Full-year sales are now $525 million to $550 million.
-
$SSYS: Sales Were Flat; The Cash-Flow Outlook Got Cut earnings_post · 2026-08-13-SSYS · Aug 14, 4:19 AM ETThe three-cent profit matched last year. Revenue missed. Management no longer promises full-year operating cash flow will be positive.
-
$FFAI: The Loss Narrowed. $1.35 Million of Sales Did Not Move the Stock earnings_post · 2026-08-13-FFAI · Aug 13, 4:38 PM ETEPS beat driven by loss reduction, not growth. H1 revenue of $1.35M highlights scale deficit.
-
$CRMD: Q3 Fungal Filing Update earnings_post · 2026-08-13-CRMD · Aug 13, 2:36 PM ETCorMedix beats Q2 estimates on revenue growth; CEO confirms supplemental filing for fungal treatment by Q3.
-
$SOAR: Q2 Prelim Beats + Vaunt/Flyte Synergy Ahead of Print earnings_pre · 2026-08-13-SOAR · Aug 13, 4:02 PM ETVolato Group reports strong preliminary Q2 results with record Vaunt growth; Flyte’s 7.5% stake and platform integration add strategic weight ahead of full earnings.
-
$LAC: Q2 Loss Narrowing, but Guidance Is the Real Test earnings_pre · 2026-08-13-LAC · Aug 13, 3:53 PM ETPre-market setup for Lithium Americas: consensus expects a narrowed loss, but the Thacker Pass capex roadmap and lithium pricing outlook will drive the post-print move.
-
$ONDS: Record Sales, Wider Loss — Scale Is Not Free Yet earnings_pre · 2026-08-13-ONDS · Aug 14, 4:31 AM ET
Revenue hit $83.8 million, well above the $68 million guess. The company still lost about $89 million, and that gap is the story.
-
$SSYS: Record Consumables, Flat Sales — New Printers Still Stalled earnings_pre · 2026-08-13-SSYS · Aug 14, 4:19 AM ET
Non-GAAP profit printed $0.03 a share, same as last year, while sales slipped and full-year cash-flow guidance was cut.
-
$CRMD: Q2 Beat Sets Stage for Fungal Disease Catalyst earnings_pre · 2026-08-13-CRMD · Aug 13, 2:34 PM ET
CorMedix beats Q2 EPS estimates; CEO signals supplemental filing for fungal treatment in Q3.